ABBV vs ISRG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intuitive Surgical, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Intuitive Surgical, Inc. · Healthcare
$451.29
+130.4% upside to fair value
Grade B
High Quality
QuantHub Verdict
ISRG has more upside to fair value
(+130.4%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ISRG |
| Current Price |
$208.05 |
$451.29 |
| Fair Value Estimate |
$217.50 |
$1,039.74 |
| Upside to Fair Value |
+4.5%
|
+130.4%
|
| Market Cap |
$367.9B |
$160.3B |
| Forward P/E |
14.9x
|
53.8x
|
| EV / EBITDA |
16.7x
|
40.5x
|
| Price / Sales |
6.1x
|
15.2x
|
| Price / FCF |
20.9x
|
64.3x
|
| Revenue Growth YoY |
+8.6%
|
+23.0%
|
| Gross Margin |
83.7%
|
66.3%
|
| Operating Margin |
34.7%
|
30.5%
|
| Return on Equity |
-129.24%
|
17.0%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
1.55%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Intuitive Surgical, Inc. is a leading healthcare company specializing in robotic-assisted surgery through its flagship da Vinci system, which has established a durable competitive moat with approximately 10,000 systems installed globally and nearly 17 million procedures performed by the end of 2024. The company benefits from a high-quality business model characterized by 85% recurring revenue, st…
Accumulation Zones
| Metric |
ABBV |
ISRG |
| Zone Low |
$163.13 |
$779.81 |
| Zone High |
$184.88 |
$883.78 |
| In Buy Zone? |
No
|
Yes
|